Arcus Biosciences Inc expected to post a loss of $1.13 a share - Earnings Preview

Arcus Biosciences

04/11/2023 03:05

* Arcus Biosciences Inc  RCUS.N   RCUS.K  is expected
to show a
fall in quarterly revenue when it reports  results on November
7. 
    * The Hayward California-based  company is expected to
report  a
18.8% decrease in revenue to $27.282 million from $33.58 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Arcus Biosciences
Inc is
for a loss of $1.13 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arcus
Biosciences
Inc is $38​, above​ its last closing price of $16.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.09       -1.10      -1.04     Beat    5.3
 Mar. 31 2023  -1.17       -1.16      -1.09     Beat    6.3
 Dec. 31 2022  -1.02       -1.07      -0.93     Beat    12.8​
 Sep. 30 2022  -1.03       -1.04      -0.90     Beat    13.3
 ​​Jun.        -0.94       -0.94      -0.93     Beat    1.2
 30 2022                                                
 Mar. 31 2022  -0.83       -0.86      -0.96     Missed  -11.5​
 Dec. 31 2021  0.07        -0.74      3.71      Beat    598.8
 Sep. 30 2021  -1.07       -1.08      -1.11     Missed  -3.2
 This summary was machine generated November 4 at 03:05 GMT.  All
figures in US dollars  unless otherwise stated